Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor
Digestive Diseases · 2024
DOI: 10.1159/000538606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases, 2024. Verfasst von Nela Stastna und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Nutritional Status, Exocrine Pancreatic Insufficiency, Indoles. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cystic fibrosis transmembrane conductance regulator modulator therapy improves nutritional status and quality of life. Clinical trials have shown pancreatic insufficiency conversion, mostly in pediatric patients treated with ivacaftor. Studies with elexacaftor/tezacaftor/ivacaftor (ETI) in older patients have not suggested restoration of exocrine pancreas function, but quality data in adults are lacking. Our aim was to show the effect of ETI in adults with cystic fibrosis (CF) on nutritional status and digestive function. We hypothesized improvement of nutritional parameters and gastrointestinal symptoms, reduction of pancreatic enzyme replacement therapy, but uncertain improvement in exocrine pancreatic function.
Methods
We prospectively enrolled adults with CF treated with ETI from August 2021 to June 2022. We measured anthropometric parameters, laboratory nutritional markers, change of fecal elastase, pancreatic enzymes replacement therapy needs, and gastrointestinal symptoms.
Results
In the cohort of 29 patients (mean age 29.1 years), 82.8% suffered exocrine pancreatic insufficiency. After ETI, mean BMI increased by 1.20 kg/m2 (p < 0.001), mean body weight by 3.51 kg (p < 0.001), albumin by 2.81 g/L, and prealbumin by 0.06 (both p < 0.001). Only 1 patient, initially pancreatic insufficient (4.5%, p < 0.001), developed pancreatic sufficiency, indicated by increased fecal elastase from 45 μg/g to 442.1 μg/g. Mean change in lipase substitution decreased by 1,969 units/kg/day (p < 0.001) and stools frequency by 1.18 per day (p < 0.001).
Conclusion
Our data suggest increased nutritional parameters, lower pancreatic substitution requirements, and improved defecation in adult CF patients on ETI. Improvement in exocrine pancreatic function might be mutation-specific and needs further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pneumology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia.
- Faculty of Medicine, Masaryk University, Brno, Czechia.
- Department of Surgery, University Hospital Brno, Brno, Czechia.
- Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czechia.
- 2nd Department of Internal Medicine - Gastroenterology and Geriatrics, University Hospital Olomouc, Olomouc, Czechia.
- Department of Gastroenterology and Digestive Endoscopy, Masaryk Memorial Cancer Institute, Brno, Czechia.
Zitieren
APA
Stastna, N., Kunovsky, L., Svoboda, M., Pokojova, E., Homola, L., Mala, M., Gracova, Z., Jerabkova, B., Skrickova, J., & Trna, J. (2024). Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor. Digestive Diseases. https://doi.org/10.1159/000538606
Vancouver
Stastna N, Kunovsky L, Svoboda M, Pokojova E, Homola L, Mala M, et al. Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor. Digestive Diseases. 2024. doi:10.1159/000538606
BibTeX
@article{Stastna2024,
author = {Stastna, Nela and Kunovsky, Lumir and Svoboda, Michal and Pokojova, Eva and Homola, Lukas and Mala, Miriam and Gracova, Zaneta and Jerabkova, Barbora and Skrickova, Jana and Trna, Jan},
title = {Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor},
journal = {Digestive Diseases},
year = {2024},
doi = {10.1159/000538606}
}
EUVIMED